Industry data reveals the barriers between prescription and long-term adherence and how to address them.

The clinical signals for GLP-1 therapy are compelling. The real-world persistence data is less so.

Industry research shows a significant gap between prescribing decisions and sustained patient adherence, with static caused by access barriers, coverage gaps, and administrative friction.

Our new infographic traces breakdowns in the GLP-1 patient journey and shows where actionable interventions can make a difference.

What you’ll learn:

• The access and affordability barriers derailing GLP-1 persistence

• Where industry data shows potential high-impact intervention points

• How pharma teams can address these barriers across the medication journey

This research applies beyond GLP-1s. If you’re managing specialty therapy access and adherence, the insights here are transferable.